Evidence map›Paper›PMID 40302158›Full record

Observational studyBrain and behavior2025

Parkinson's Disease, Speech and Neurosurgery.

Thomas Ollivier, Serge Pinto, Anne-Sophie Rolland, Emeline Cailliau, Gustavo Touzet, S Thobois, A Eusebio, E Hainque, T Rouaud, S Drapier and 18 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02360683 (Predictive Factors for Therapeutic Response of Subthalamic Stimulation on Quality of Live in Parkinson's Disease), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02360683 completednot on this map

Predictive Factors for Therapeutic Response of Subthalamic Stimulation on Quality of Live in Parkinson's Disease

TypeobservationalSponsorUniversity Hospital, LilleRan2013 to 2025Enrolled700ConditionsParkinson's DiseaseArmspatients with Parkinson's disease
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Thomas OllivierCHU Lille Department of Medical Pharmacology, University of Lille, Lille Neuroscience and Cognition INSERM, U1172, LiCEND, NS-Park/F-CRIN Network, Lille, France.ORCID https://orcid.org/0000-0002-3609-5211
Serge PintoCNRS, LPL, Aix-Marseille Université, Aix-en-Provence, France.
Anne-Sophie RollandCHU Lille Department of Medical Pharmacology, University of Lille, Lille Neuroscience and Cognition INSERM, U1172, LiCEND, NS-Park/F-CRIN Network, Lille, France.
Emeline CailliauBiostatistics Department, CHU Lille, Lille, France.
Gustavo TouzetNeurosurgical Department, Lille University Medical Center, Lille, France.
S ThoboisFaculté de Médecine Lyon Sud Charles Mérieux; CNRS, Institut des Sciences Cognitives, Univ Lyon, Université Claude Bernard Lyon 1, Bron, France.
A EusebioService de Neurologie et Pathologie du Mouvement and UMR CNRS, AP-HM, Hôpital de La Timone, Aix-Marseille Université, Aix-en-Provence, France.
E HainqueDépartement de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Faculté de Médecine de Sorbonne Université, UMR S 1127, INSERM U 1127; CNRS UMR 7225; and Institut du Cerveau et de la Moëlle Epinière, NS-PARK/FCRIN Network, Paris, France.
T RouaudDepartment of Neurology, Nantes University Hospital, Nantes Cedex, NS-Park/FCRIN Network, Nantes, France.
S DrapierDepartment of Neurology, Rennes University Hospital, CIC INSERM 1414, NS-PARK/FCRIN Network, Rennes Cedex, France.
D GuehlCHU de Bordeaux, Center Expert Parkinson, Institut des Maladies Neuro-Dégénératives, Bordeaux, France.
D MalteteDepartment of Neurology, Rouen University Hospital and University of Rouen, Rouen, France.
M AnheimService de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
O Lagha BoukbizaService de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
C GiordanaNeurology Department, Center Hospitalier Universitaire de Nice, Université Côté d'Azur, Nice, France.
M TirDepartment of Neurology, Department of Neurosurgery, Expert Center for Parkinson's Disease, Amiens University Hospital, EA 4559 Laboratoire de Neurosciences Fonctionnelles et Pathologie (LNFP) Université de Picardie Jules Verne, University of Picardy Jules Verne (UPJV), NS-PARK/FCRIN Network, Amiens, France.
L HopesNeurology Department, Nancy University Hospital, Nancy, France.
C HubschHôpital Fondation Ophtalmologique A de Rothschild, Unité James Parkinson, NS-Park French Network, Paris, France.
B JarrayaPôle Neurosciences, Foch Hospital, Suresnes, France.
A MarquesNeurology Department, Université Clermont Auvergne, IGCNC, Clermont-Ferrand University Hospital, NS-PARK/FCRIN Network, Clermont-Ferrand, France.
C BrefelDepartment of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Center d'Investigation Clinique CIC1436, ToNIC UMR 1214, NeuroToul COEN Center, and NS-PARK/FCRIN Network, University Hospital of Toulouse, University of Toulouse 3, INSERM, Toulouse, France.
O RascolDepartment of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Center d'Investigation Clinique CIC1436, ToNIC UMR 1214, NeuroToul COEN Center, and NS-PARK/FCRIN Network, University Hospital of Toulouse, University of Toulouse 3, INSERM, Toulouse, France.
J C CorvolDépartement de Neurologie, Hôpital Pitié-Salpêtrière, AP-HP, Faculté de Médecine de Sorbonne Université, UMR S 1127, INSERM U 1127; CNRS UMR 7225; and Institut du Cerveau et de la Moëlle Epinière, NS-PARK/FCRIN Network, Paris, France.
I BenatruService de Neurologie, Center Expert Parkinson, CIC-INSERM 1402, CHU Poitiers, NS-PARK/FCRIN Network, Poitiers, France.
Luc DefebvreCHU Lille Department of Medical Pharmacology, University of Lille, Lille Neuroscience and Cognition INSERM, U1172, LiCEND, NS-Park/F-CRIN Network, Lille, France.
David DevosCHU Lille Department of Medical Pharmacology, University of Lille, Lille Neuroscience and Cognition INSERM, U1172, LiCEND, NS-Park/F-CRIN Network, Lille, France.
Caroline MoreauCHU Lille Department of Medical Pharmacology, University of Lille, Lille Neuroscience and Cognition INSERM, U1172, LiCEND, NS-Park/F-CRIN Network, Lille, France.
French PREDISTIM study group

Funding

France Parkinson charity Association (228 K€): PREDI-STIM studyFrench Ministry of Health (533 K€), PREDI-STIM Study: Multicentric study of the predictive factors of the therapeutic response to subthalamic stimulation on the long-term quality of life and study of the pharmacogenetic factors of the L-dopa treatment response in Parkinson's disease Protocol 2011_41;DrugAgencyIDFrench Ministry of Health (533 K€), PREDI-STIM Study: Multicentric study of the predictive factors of the therapeutic response to subthalamic stimulation on the long-term quality of life and study of the pharmacogenetic factors of the L-dopa treatment response in Parkinson's disease Protocol 2013-A00193-42;ClinicalTrials.govFrench Ministry of Health (533 K€), PREDI-STIM Study: Multicentric study of the predictive factors of the therapeutic response to subthalamic stimulation on the long-term quality of life and study of the pharmacogenetic factors of the L-dopa treatment response in Parkinson's disease Protocol IDFrench Ministry of Health (533 K€), PREDI-STIM Study: Multicentric study of the predictive factors of the therapeutic response to subthalamic stimulation on the long-term quality of life and study of the pharmacogenetic factors of the L-dopa treatment response in Parkinson's disease Protocol NCT02360683
6 · The paper itself

Abstract

backgroundSpeech impairment is a recognized but unpredictable adverse effect of sub-thalamic nucleus deep brain stimulation (STN-DBS) for Parkinson's disease (PD).

objectivesTo evaluate the prevalence of speech impairment 1 year after STN-DBS in PD patients and to determine the predictive factors for speech outcome following STN-DBS.

methodsData for 417 patients from the French national PREDISTIM study were collected preoperatively. The combined effect of medical treatment and surgery on speech was compared using specific items from dedicated clinical scales (MDS-UPDRS III.1: primary endpoint) and patient self-assessment questionnaires (items 34 and 35 of the PDQ39: secondary endpoints). For each variable, three patient groups were generated according to speech outcome at 1 year: worsening, stability, and improvement. In the second step analysis, the three groups were compared for demographic and clinical variables at baseline and STN-DBS parameters.

resultsThere was a significant deterioration in speech of all considered items 1 year after combined STN-DBS and dopaminergic treatment. Four predictive factors for speech deterioration were detected: (i) the absence of preoperative speech impairment (p < 0.001); (ii) severity of motor activity of daily living (MDS-UPDRS II off total score) (p = 0.037); (iii) high-intensity stimulation of the left electrode (i.e., above 3.6 V) (p = 0.046); and (iv) the absence of any change in non-motor experiences of daily life (MDS-UPDRS I total score) (p = 0.048).

conclusionsSpeech outcome should be carefully monitored after STN-DBS, especially in PD patients without preoperative speech impairment, with motor difficulties in daily-living activities, and with increased left electrode intensity.

trial registrationClinicalTrials.gov identifier: NCT02360683.

Indexed as

Deep Brain StimulationParkinson DiseaseSpeech DisordersAgedFemaleHumansMaleMiddle AgedSeverity of Illness IndexSpeechSubthalamic NucleusTreatment OutcomeParkinson's diseasespeech disorderssub‐thalamic deep brain stimulation

Identifiers

PMID40302158
PMCPMC12040730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.